This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ellodi Pharmaceuticals, L.p.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Mark Marino: Innovator in Eosinophilic Esophagitis Treatment
Introduction
Mark Marino is a notable inventor based in Blue Bell, PA (US). He has made significant contributions to the field of medicine, particularly in the treatment of eosinophilic esophagitis. His innovative approaches aim to improve patient outcomes while minimizing side effects.
Latest Patents
Mark Marino holds a patent for "Methods of treating eosinophilic esophagitis and reducing candidiasis." This patent discloses methods for treating eosinophilic esophagitis with corticosteroids. The methods outlined in the patent result in reduced corticosteroid side effects, such as candidiasis. The patent provides dosages, formulations, and methods for the administration of corticosteroids, showcasing his commitment to advancing medical treatments.
Career Highlights
Mark Marino is associated with Ellodi Pharmaceuticals, L.P., where he continues to work on innovative solutions in the pharmaceutical industry. His expertise and dedication to research have positioned him as a valuable asset in the field.
Collaborations
Mark collaborates with James Nezamis, contributing to the development of new treatment methodologies and enhancing the effectiveness of existing therapies.
Conclusion
Mark Marino's work in the treatment of eosinophilic esophagitis exemplifies the impact of innovation in medicine. His patent and ongoing contributions to Ellodi Pharmaceuticals highlight his role as a key figure in advancing healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile